Poster

Treating Major Depressive Disorder After Suboptimal Response to Antidepressant Treatment: Where Do Digital Mental Health Tools Fit in?

Abstract: Introduction: Less than half of patients receiving first-line antidepressant (ADT) treatment for major depressive disorder (MDD) achieve remission. When considering the next tre...

08/20/2024

Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: Post-Hoc Analyses of Two Phase 3 Clinical Trials

Abstract: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). Valbenazine effect sizes (Cohen’s d) for th...

08/20/2024

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen

Abstract: Background: The long-acting injectable aripiprazole lauroxil (AL) initiated using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg dose of ...

08/20/2024

Treatment Patterns and Persistence Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray

Abstract: BACKGROUND: Durability of esketamine clinical benefits for treatment resistant depression (TRD) may correlate with treatment sessions completed and therapy persistence. Underst...

08/20/2024

Safety and Exposure of TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA) Formulation of Risperidone, in Adolescent and Young Adult Patients With Schizophrenia: Results From the Phase 3 RISE and SHINE Studies

Abstract: Background: Two phase 3 trials evaluating TV-46000 for schizophrenia enrolled patients aged 13–65 years. Adolescents aged 13–18 years and young adults aged 19–21 years who recei...

08/20/2024

Sustained Chorea Improvements with Long-Term, Once-Daily Valbenazine in Adults with Huntington’s Disease

Abstract: Background: In the phase 3 KINECT®-HD (NCT04102579) study, valbenazine significantly improved chorea versus placebo in adults with Huntington’s disease (HD). KINECT®-HD2 (NCT044...

08/20/2024

Switching Patients With Schizophrenia From Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: An Exploration of Population Pharmacokinetic–Based Strategies

Abstract: Background This analysis used population pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate o...

08/20/2024

Switching Patients With Schizophrenia to TV-46000, a Long-Acting Subcutaneous Antipsychotic, From Risperidone Microspheres (R064766): An Exploration of Population Pharmacokinetic-Based Strategies

Abstract: Background: This analysis used pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from R064766 (a once-every-2-weeks [q2w] intramuscula...

08/20/2024

Tackling Myths and Misconceptions about Long-Acting Injectables in Schizophrenia

While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, includ...

08/20/2024

The Junonia Postpartum Depression (PPD) Study: Assessing PPD Care Models in the USA

Abstract: Objective: To describe characteristics of patients from a prospective observational study evaluating postpartum depression (PPD) care pathways. Methods: Junonia is an ongoing ...

08/20/2024